Medivation Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Partners Reit OP Rating Following Medivation (MDVN) 1Q Results
May 8, 2015 9:45 AM EDTLeerink Partners maintains an Outperform rating on Medivation, Inc. (NASDAQ: MDVN), with their price target set at $128. Leerink believes that the demand for Xtandi appears to be solid, and expects a continued uptake of Xtandi over the rest of the year. MDVN reported US Xtandi sales were $224M in 1Q15. While this was in the... More
Medivation (MDVN) PT Lifted at UBS Despite Q1 'Miss'
May 8, 2015 9:40 AM EDTUBS analyst Matthew Roden reiterated a Buy rating and boosted his price target on Medivation (NASDAQ: MDVN) to $142.00 (from $130.00) despite a miss on US Xtandi sales by $14m. The firm remain encouraged by the results since only nominal double-digit growth is required to beat 2015... More
Medivation (MDVN) Misses Q1 EPS by 10c
May 7, 2015 4:17 PM EDTMedivation (NASDAQ: MDVN) reported Q1 EPS of $0.17, $0.10 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $127.8 million versus the consensus estimate of $149 million.
U.S. net sales of XTANDI (enzalutamide) capsules, as reported by Astellas Pharma Inc., were $224.0 million for the quarter (+80% vs. prior year). On its February 25, 2015 earnings call, Medivation stated its... More
